Literature DB >> 27779691

miR-4262 promotes the proliferation of human cutaneous malignant melanoma cells through KLF6-mediated EGFR inactivation and p21 upregulation.

Dingwei Zhang1, Zhangjun Li1, Yanfei Zhang1, Chen Tu1, Jia Huo1, Yan Liu1.   

Abstract

Alterations in the levels and functions of microRNAs (miRs) have been associated with carcinogenesis. In this study, we investigated the role and underlying mechanism of miR-4262 in the proliferation of human cutaneous malignant melanoma (CMM) cells. The expression levels of miR-4262 were significantly upregulated in cancerous tissues compared with those in matched adjacent normal tissues from 110 CMM patients. miR-4262 was also regulated in five types of CMM cell lines, displaying an opposite expression pattern to that of Kruppel-like 6 (KLF6), a proven tumor suppressor in several cancers other than CMM. KLF6 overexpression sharply reduced A375 cell proliferation, suppressed the activation of epidermal growth factor receptor (EGFR) and increased p21 expression levels, while knockdown of KLF6 by siRNA transfection had an opposite effect. Furthermore, KLF6 was proven to be a direct target gene of miR-4262 by bioinformatic analysis and KLF6‑3'UTR luciferase reporter assay. Finally, our data on miR-4262 mimic and inhibitor transfection indicated that miR-4262 could markedly reduce the expression of KLF6 protein and had a stimulatory effect on A375 cell proliferation. Our findings indicate that KLF6 acts as a tumor suppressor in CMM cells and miR-4262 promotes the proliferation of CMM cells through KLF6-mediated EGFR inactivation and p21 upregulation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27779691     DOI: 10.3892/or.2016.5190

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

1.  miR-4262 regulates chondrocyte viability, apoptosis, autophagy by targeting SIRT1 and activating PI3K/AKT/mTOR signaling pathway in rats with osteoarthritis.

Authors:  Wencai Sun; Yintai Li; Suizhuan Wei
Journal:  Exp Ther Med       Date:  2017-11-06       Impact factor: 2.447

Review 2.  MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.

Authors:  Soudeh Ghafouri-Fard; Mahdi Gholipour; Mohammad Taheri
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

3.  KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.

Authors:  Melyssa S Roberts; Lindsey J Anstine; Viviane S Finke; Benjamin L Bryson; Bryan M Webb; Kristen L Weber-Bonk; Darcie D Seachrist; Parth R Majmudar; Ruth A Keri
Journal:  Breast Cancer Res       Date:  2020-06-18       Impact factor: 6.466

4.  miR-4262, low level of which predicts poor prognosis, targets proto-oncogene CD163 to suppress cell proliferation and invasion in gastric cancer.

Authors:  Hongzhi Zhang; Huijuan Jiang; Huixiang Zhang; Juncai Liu; Xigang Hu; Lei Chen
Journal:  Onco Targets Ther       Date:  2019-01-15       Impact factor: 4.147

5.  Involvement of miR-4262 in paclitaxel resistance through the regulation of PTEN in non-small cell lung cancer.

Authors:  Hongwen Sun; Xiaoting Zhou; Yanan Bao; Guosheng Xiong; Yue Cui; Hua Zhou
Journal:  Open Biol       Date:  2019-07-24       Impact factor: 6.411

6.  CRNDE Contributes Cervical Cancer Progression by Regulating miR-4262/ZEB1 Axis.

Authors:  Lu Ren; Shaoqin Yang; Qinxue Cao; Jun Tian
Journal:  Onco Targets Ther       Date:  2021-01-13       Impact factor: 4.147

7.  LncRNA KASRT Serves as a Potential Treatment Target by Regulating SRSF1-Related KLF6 Alternative Splicing and the P21/CCND1 Pathway in Osteosarcoma: An In Vitro and In Vivo Study.

Authors:  Kai Chen; Cheng Li; Shuai Huang; Yu Chen; Xiaodong Zhu
Journal:  Front Oncol       Date:  2021-09-09       Impact factor: 6.244

Review 8.  Non-coding RNAs in skin cancers:Biological roles and molecular mechanisms.

Authors:  Fei Liu; Shenglong Li
Journal:  Front Pharmacol       Date:  2022-08-10       Impact factor: 5.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.